Ian O. Ellis
About
Ian O. Ellis is a scholar working on Oncology, Cancer Research and Molecular Biology.
According to data from OpenAlex, Ian O. Ellis has authored 986 papers receiving a total of 62.0k indexed citations (citations by other indexed papers that have themselves been cited), including 468 papers in Oncology, 462 papers in Cancer Research and 294 papers in Molecular Biology. Recurrent topics in Ian O. Ellis's work include Breast Cancer Treatment Studies (378 papers), Breast Lesions and Carcinomas (248 papers) and HER2/EGFR in Cancer Research (188 papers). Ian O. Ellis is often cited by papers focused on Breast Cancer Treatment Studies (378 papers), Breast Lesions and Carcinomas (248 papers) and HER2/EGFR in Cancer Research (188 papers). Ian O. Ellis collaborates with scholars based in United Kingdom, United States and Egypt. Ian O. Ellis's co-authors include C.W. Elston, Emad A. Rakha, Andrew R. Green, Sarah E. Pinder, J.F.R. Robertson, Andrew H.S. Lee, Jorge S. Reis‐Filho, R.W. Blamey, C.W. Elston and Robert I. Nicholson and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and The Lancet.
In The Last Decade
Ian O. Ellis
961 papers receiving 60.6k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Ian O. Ellis United Kingdom | 111 | 28.9k | 27.4k | 20.7k | 14.7k | 7.6k | 986 | 62.0k | ||
| Giuseppe Viale Italy | 113 | 29.3k 1.0× | 26.1k 1.0× | 13.1k 0.6× | 12.6k 0.9× | 4.8k 0.6× | 768 | 55.3k | ||
| Gabriel N. Hortobágyi United States | 149 | 54.2k 1.9× | 37.1k 1.4× | 22.9k 1.1× | 12.7k 0.9× | 8.8k 1.2× | 1.1k | 88.3k | ||
| Charles M. Perou United States | 112 | 39.5k 1.4× | 39.3k 1.4× | 40.5k 2.0× | 9.0k 0.6× | 11.3k 1.5× | 512 | 82.8k | ||
| Larry Norton United States | 98 | 29.6k 1.0× | 16.0k 0.6× | 13.7k 0.7× | 5.0k 0.3× | 8.4k 1.1× | 532 | 50.7k | ||
| Matt van de Rijn United States | 86 | 19.3k 0.7× | 16.4k 0.6× | 23.4k 1.1× | 6.0k 0.4× | 4.9k 0.6× | 251 | 50.2k | ||
| Razelle Kurzrock United States | 119 | 24.9k 0.9× | 13.3k 0.5× | 21.0k 1.0× | 10.0k 0.7× | 2.4k 0.3× | 1.2k | 60.4k | ||
| Jorge S. Reis‐Filho United States | 100 | 18.0k 0.6× | 16.4k 0.6× | 17.1k 0.8× | 7.1k 0.5× | 4.2k 0.6× | 521 | 37.9k | ||
| Eric P. Winer United States | 118 | 36.8k 1.3× | 20.2k 0.7× | 10.7k 0.5× | 5.6k 0.4× | 6.8k 0.9× | 737 | 56.6k | ||
| Daniel F. Hayes United States | 95 | 27.3k 0.9× | 21.8k 0.8× | 13.3k 0.6× | 6.5k 0.4× | 5.9k 0.8× | 412 | 47.9k | ||
| Norman Wolmark United States | 111 | 39.2k 1.4× | 40.3k 1.5× | 7.6k 0.4× | 21.8k 1.5× | 11.0k 1.4× | 532 | 68.8k |
Countries citing papers authored by Ian O. Ellis
Since
Specialization
Citations
This map shows the geographic impact of Ian O. Ellis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ian O. Ellis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ian O. Ellis more than expected).
Fields of papers citing papers by Ian O. Ellis
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Ian O. Ellis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ian O. Ellis. The network helps show where Ian O. Ellis may publish in the future.
Co-authorship network of co-authors of Ian O. Ellis
This figure shows the co-authorship network connecting the top 25 collaborators of Ian O. Ellis. A scholar is included among the top collaborators of Ian O. Ellis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ian O. Ellis. Ian O. Ellis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Coombes, R. Charles, William E. Hart, Darius Francescatti, et al.. (2024). Performance of a novel spectroscopy-based tool for adjuvant therapy decision-making in hormone receptor-positive breast cancer: a validation study. Breast Cancer Research and Treatment. 205(2). 349–358.
2.
Lashen, Ayat, Michael S. Toss, Islam M. Miligy, et al.. (2024). Nottingham prognostic x (NPx ): a risk stratification tool in ER ‐positive HER2 ‐negative breast cancer: a validation study. Histopathology. 85(3). 468–477.
3.
Katayama, Ayaka, Jane Starczynski, Michael S. Toss, et al.. (2022). The frequency and clinical significance of centromere enumeration probe 17 alterations in human epidermal growth factor receptor 2 immunohistochemistry‐equivocal invasive breast cancer. Histopathology. 81(4). 511–519.
4.
Pu, Xuan, Sarah J. Storr, Emad A. Rakha, et al.. (2018). High nuclear MSK1 is associated with longer survival in breast cancer patients. Journal of Cancer Research and Clinical Oncology. 144(3). 509–517.
5.
Ansari, Rokaya El, Madeleine L. Craze, Islam M. Miligy, et al.. (2018). The amino acid transporter SLC7A5 confers a poor prognosis in the highly proliferative breast cancer subtypes and is a key therapeutic target in luminal B tumours. Breast Cancer Research. 20(1). 21–21.
6.
Staley, James R, James Blackshaw, Mihir Kamat, et al.. (2016). PhenoScanner: a database of human genotype–phenotype associations. Bioinformatics. 32(20). 3207–3209.
7.
Aleskandarany, Mohammed A., Ola H. Negm, Andrew R. Green, et al.. (2014). Epithelial mesenchymal transition in early invasive breast cancer: an immunohistochemical and reverse phase protein array study. Breast Cancer Research and Treatment. 145(2). 339–348.
8.
Barros, F., Tarek M.A. Abdel-Fatah, Paul M. Moseley, et al.. (2014). Characterisation of HER heterodimers in breast cancer using in situ proximity ligation assay. Breast Cancer Research and Treatment. 144(2). 273–285.
9.
Mhlanga, Joyce, Sarah Doyle, Jonathan J. James, et al.. (2011). The prognostic significance of computerised tomography findings in women with liver metastases from breast cancer. The Breast. 20(5). 455–459.
10.
Cuzick, Jack, Mitch Dowsett, Sílvia Pineda, et al.. (2011). Prognostic Value of a Combined Estrogen Receptor, Progesterone Receptor, Ki-67, and Human Epidermal Growth Factor Receptor 2 Immunohistochemical Score and Comparison With the Genomic Health Recurrence Score in Early Breast Cancer. Journal of Clinical Oncology. 29(32). 4273–4278.
11.
Barros, F., Desmond G. Powe, Ian O. Ellis, & Andrew R. Green. (2010). Understanding the HER family in breast cancer: interaction with ligands, dimerization and treatments. Histopathology. 56(5). 560–572.
12.
Powe, Desmond G., Hany Onsy Habashy, Tarek M.A. Abdel-Fatah, et al.. (2009). Investigating AP-2 and YY1 protein expression as a cause of high HER2 gene transcription in breast cancers with discordant HER2 gene amplification. Breast Cancer Research. 11(6). R90–R90.
13.
Taneja, Sangeeta, Andrew Evans, Emad A. Rakha, et al.. (2008). The mammographic correlations of a new immunohistochemical classification of invasive breast cancer. Clinical Radiology. 63(11). 1228–1235.
14.
Chin, Suet‐Feung, Andrew E. Teschendorff, John C. Marioni, et al.. (2007). High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer. Genome biology. 8(10). R215–R215.
15.
Madjd, Zahra, Ian Spendlove, Ian O. Ellis, S Pinder, & LG Durrant. (2005). Total Loss of MHC Class I is an Independent Indicator of Good Prognosis in Breast Cancer. SHILAP Revista de lepidopterología. 34. 51–52.
16.
Kurien, Thomas, Emma C. Paish, J Ronan, et al.. (2005). Three dimensional reconstruction of a human breast carcinoma using routine laboratory equipment and immunohistochemistry. Journal of Clinical Pathology. 58(9). 968–972.
17.
Willsher, Peter C., I. H. Leach, Ian O. Ellis, et al.. (1997). Male breast cancer: pathological and immunohistochemical features.. PubMed. 17(3C). 2335–8.
18.
Eliopoulos, Aristides G., Demetrios�� Spandidos, David Barnes, et al.. (1995). Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy. British Journal of Cancer. 72(5). 1259–1266.
19.
Cannon, P., et al.. (1992). Surgery versus tamoxifen in selected elderly patients with operable breast cancer Early results of a randomised trial. Breast Cancer Research and Treatment. 23. 182.
20.
Poller, David, M Galea, Derek Pearson, et al.. (1991). Nuclear and flow cytometric characteristics associated with overexpression of the c-erbB-2 oncoprotein in breast carcinoma. Breast Cancer Research and Treatment. 20(1). 3–10.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Giuseppe Viale Breakdown of academic impact, for papers by Gabriel N. Hortobágyi Breakdown of academic impact, for papers by Charles M. Perou Breakdown of academic impact, for papers by Larry Norton Breakdown of academic impact, for papers by Matt van de Rijn Breakdown of academic impact, for papers by Razelle Kurzrock Breakdown of academic impact, for papers by Jorge S. Reis‐Filho Breakdown of academic impact, for papers by Eric P. Winer Breakdown of academic impact, for papers by Daniel F. Hayes Breakdown of academic impact, for papers by Norman Wolmark